ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced the ...

Earlier this week, Franco-German peer Sartorius reported preliminary annual results that beat expectations and posted a 23.1% ...

In early phase trials innovative designs offer potential for improvements in efficiency and decision-making. Determining the ...

BluGlass, a company pioneering lasers for the quantum, defence, and biotech markets, has filed three US patent applications ...

ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today announced that it will release financial results for the fourth quarter and full year 2024 ...

The ClearBridge Large Cap Growth ESG Strategy underperformed its Russell 1000 Growth Index benchmark in the fourth quarter.

The scrims have been removed from the windows of the Biotechnology Lab at The Living with the Land attraction in EPCOT ...

Bank of America Securities analyst Michael Ryskin reiterated a Buy rating on Icon (ICLR – Research Report) today and set a price target of ...

During our latest visit to EPCOT, we noticed the Biotechnology Lab seen from the Living with the Land ride has new been ...

TD Cowen adjusted its financial outlook for ICON plc (NASDAQ:ICLR), a global provider of drug development solutions and services to the pharmaceutical, biotechnology, and medical device industries.

Moderna received a $590 million award from the U.S. government to speed development of a vaccine that could be used to fight bird flu.